# Gilead Completes $5 Billion Acquisition of ADC Specialist Tubulis

> ma · REPORTED · 2026-05-21

On May 21, 2026, Gilead Sciences announced the completion of its previously announced acquisition of Munich-based Tubulis GmbH for $3.15 billion upfront plus up to $1.85 billion in milestone payments, adding the next-generation Tubutecan ADC platform, lead asset TUB-040 in Phase 1b/2 for ovarian cancer, and establishing Munich as a dedicated ADC innovation hub within Gilead's oncology organization.

- Company: Gilead Sciences / Tubulis
- Sector: biotech
- Primary source: https://www.gilead.com/news/news-details/2026/gilead-sciences-completes-acquisition-of-tubulis-further-strengthening-oncology-portfolio

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.